INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,485,000 | +6.1% | 91,263 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $1,399,000 | +220.9% | 85,868 | +192.5% | 0.00% | – |
| Q3 2021 | $436,000 | -34.0% | 29,361 | -11.3% | 0.00% | – |
| Q2 2021 | $661,000 | +15.0% | 33,100 | +32.9% | 0.00% | – |
| Q1 2021 | $575,000 | -9.3% | 24,899 | -3.0% | 0.00% | – |
| Q4 2020 | $634,000 | -32.7% | 25,660 | +12.9% | 0.00% | -100.0% |
| Q3 2020 | $942,000 | -29.3% | 22,723 | -18.3% | 0.00% | 0.0% |
| Q2 2020 | $1,332,000 | -32.0% | 27,804 | -10.7% | 0.00% | -50.0% |
| Q1 2020 | $1,960,000 | -63.4% | 31,129 | -27.9% | 0.00% | -50.0% |
| Q4 2019 | $5,348,000 | +153.7% | 43,155 | +35.8% | 0.00% | +100.0% |
| Q3 2019 | $2,108,000 | -27.7% | 31,767 | -13.3% | 0.00% | 0.0% |
| Q2 2019 | $2,915,000 | -57.0% | 36,632 | -39.5% | 0.00% | -66.7% |
| Q1 2019 | $6,776,000 | +10.5% | 60,573 | -0.5% | 0.01% | 0.0% |
| Q4 2018 | $6,133,000 | -17.1% | 60,847 | +3.9% | 0.01% | 0.0% |
| Q3 2018 | $7,398,000 | +51.4% | 58,548 | +0.5% | 0.01% | +20.0% |
| Q2 2018 | $4,888,000 | +62.0% | 58,257 | +18.7% | 0.01% | +66.7% |
| Q1 2018 | $3,018,000 | +334.9% | 49,059 | +312.8% | 0.00% | +200.0% |
| Q4 2017 | $694,000 | +129.8% | 11,885 | +128.5% | 0.00% | – |
| Q3 2017 | $302,000 | -90.5% | 5,202 | -80.2% | 0.00% | -100.0% |
| Q2 2017 | $3,188,000 | +0.6% | 26,335 | -6.0% | 0.00% | -20.0% |
| Q1 2017 | $3,168,000 | +81.4% | 28,007 | +74.2% | 0.01% | +150.0% |
| Q4 2016 | $1,746,000 | +52.2% | 16,074 | +130.6% | 0.00% | 0.0% |
| Q3 2016 | $1,147,000 | +43.2% | 6,970 | +24.1% | 0.00% | +100.0% |
| Q2 2016 | $801,000 | +64.1% | 5,615 | +47.7% | 0.00% | 0.0% |
| Q1 2016 | $488,000 | -25.7% | 3,801 | -13.5% | 0.00% | 0.0% |
| Q4 2015 | $657,000 | -8.8% | 4,396 | +1.3% | 0.00% | 0.0% |
| Q3 2015 | $720,000 | -54.9% | 4,338 | -34.4% | 0.00% | -66.7% |
| Q2 2015 | $1,596,000 | +25.8% | 6,610 | +46.9% | 0.00% | 0.0% |
| Q1 2015 | $1,269,000 | +277.7% | 4,499 | +109.0% | 0.00% | +200.0% |
| Q4 2014 | $336,000 | -54.0% | 2,153 | -30.3% | 0.00% | -50.0% |
| Q2 2014 | $731,000 | – | 3,088 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |